Page last updated: 2024-10-26

dipyridamole and Leukemia P388

dipyridamole has been researched along with Leukemia P388 in 10 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Leukemia P388: An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.

Research Excerpts

ExcerptRelevanceReference
"Dipyridamole, a nucleoside membrane transport inhibitor, enhanced the cytotoxicity of epirubicin for mouse leukemia P388 cells by a factor of 1."3.69[Studies on reversing effect of multidrug resistance by dipyridamole. I. modulation of epirubicin-induced effects on cell proliferation and cell cycle by dipyridamole]. ( Furusawa, S; Hayashi, A; Sasaki, K; Takayanagi, M; Takayanagi, Y, 1996)
"Dipyridamole alone was minimally cytotoxic in both of the doxorubicin-resistant cell line (P388/DOX) and the sensitive parent cell line (P388/S), but reversed pirarubicin-resistance in a dose-related manner in P388/DOX cells."1.28Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells. ( Fujimura, T; Furusawa, S; Kawauchi, H; Sasaki, K; Takayanagi, Y, 1991)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19904 (40.00)18.7374
1990's5 (50.00)18.2507
2000's1 (10.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, P1
Chien, PY1
Khan, AR1
Sheikh, S1
Ali, SM1
Ahmad, MU1
Ahmad, I1
Hayashi, A2
Furusawa, S3
Takayanagi, M2
Takayanagi, Y2
Sasaki, K3
Takasyanagi, Y1
Lum, CT1
Marz, R1
Plagemann, PG4
Wohlhueter, RM2
Ramu, A2
Ramu, N2
Rosario, LM1
Fujimura, T1
Kawauchi, H1
Aran, JM1
Woffendin, C1

Other Studies

10 other studies available for dipyridamole and Leukemia P388

ArticleYear
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
    Anti-cancer drugs, 2006, Volume: 17, Issue:1

    Topics: Animals; Antineoplastic Agents; Body Weight; Cardiolipins; Cell Proliferation; Deoxycytidine; Dipyri

2006
[Studies on reversing effect of multidrug resistance by dipyridamole. I. modulation of epirubicin-induced effects on cell proliferation and cell cycle by dipyridamole].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 1996, Volume: 116, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Cell Cycle; Cell Division; Dipyridamole; Dose-Response Relatio

1996
[Studies on reversing effect of multidrug resistance by dipyridamole. II. Inhibition of epirubicin efflux from resistant cells by dipyridamole and its pharmacological effect].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 1996, Volume: 116, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Dipyridamole; Dose-Response Relationship, Drug; Drug Resistanc

1996
Adenosine transport and metabolism in mouse leukemia cells and in canine thymocytes and peripheral blood leukocytes.
    Journal of cellular physiology, 1979, Volume: 101, Issue:2

    Topics: Adenosine; Adenosine Triphosphate; Animals; Biological Transport; Coformycin; Concanavalin A; Dipyri

1979
Circumvention of multidrug-resistance in P388 cells is associated with a rise in the cellular content of phosphatidylcholine.
    Biochemical pharmacology, 1991, May-15, Volume: 41, Issue:10

    Topics: Animals; Cell Membrane; Cell Membrane Permeability; Choline; Digitonin; Dipyridamole; Drug Resistanc

1991
Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
    Research communications in chemical pathology and pharmacology, 1991, Volume: 71, Issue:3

    Topics: Animals; Cell Survival; Dipyridamole; Doxorubicin; Drug Resistance; Drug Synergism; Leukemia P388; T

1991
Na(+)-dependent, active nucleoside transport in mouse spleen lymphocytes, leukemia cells, fibroblasts and macrophages, but not in equivalent human or pig cells; dipyridamole enhances nucleoside salvage by cells with both active and facilitated transport.
    Biochimica et biophysica acta, 1990, Jun-11, Volume: 1025, Issue:1

    Topics: Animals; Biological Transport, Active; Cells, Cultured; Dipyridamole; Fibroblasts; Formycins; Humans

1990
Use of formycin B as a general substrate for measuring facilitated nucleoside transport in mammalian cells.
    Biochimica et biophysica acta, 1989, Jan-17, Volume: 1010, Issue:1

    Topics: Animals; Antibiotics, Antineoplastic; Biological Transport, Active; Cell Line; Dipyridamole; Formyci

1989
Circumvention of adriamycin resistance by dipyridamole analogues: a structure-activity relationship study.
    International journal of cancer, 1989, Mar-15, Volume: 43, Issue:3

    Topics: Animals; Dipyridamole; Doxorubicin; Drug Resistance; Leukemia P388; Leukemia, Experimental; Mice; Mo

1989
Effects of nucleoside transport inhibitors on the salvage and toxicity of adenosine and deoxyadenosine in L1210 and P388 mouse leukemia cells.
    Cancer research, 1985, Volume: 45, Issue:12 Pt 1

    Topics: Adenosine; Animals; Biological Transport; Coformycin; Deoxyadenosines; Dipyridamole; Inosine; Leukem

1985